EMERYVILLE, Calif., March 16 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time).  Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software.  For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through April 6, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer.  Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing.  For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals, Inc.

SOURCE Onyx Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.onyx-pharm.com